Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

The Food and Drug Administration (FDA) has approved Weltruza ™ (olanzapine) as the first once-monthly subcutaneous long-acting injectable (LAI) for the treatment of schizophreni ...

Experts at the 2026 Fall Clinical Dermatology Conference review landmark drug approvals, emerging pipelines, and updated ...

Serum ferritin threshold of less than or equal to 20ng/mL is suggested for children ages 9 months to 4 years. HealthDay News — In guidelines issued by the American Society of Hematology and published ...

Officials say low vaccination rates in rural communities are fueling the spread of the highly contagious virus.

Key insights from Fall Clinical 2026 on diagnosing and managing inflammatory skin conditions and post-inflammatory dyspigmentation in patients with skin of color.

Findings seen among pediatric patients presenting to the emergency department with moderate-to-severe acute pain ...

Nearly 1 in 3 patients with systemic lupus erythematosus (SLE) are taking a supplement–medication combination with potential for an interaction, according to ...

Key takeaways from the 26th annual Fall Clinical Dermatology Conference held in Las Vegas, Nevada were published.

Phase 3 HER2CLIMB-05 trial demonstrates a 35.9% reduction in risk of disease progression or death with maintenance tucatinib combination.

In national prospective study, 2.9% of those undergoing anesthesia reported receiving GLP-1 receptor agonists.

Phase 3 PROPEL 3 trial results show daily oral infigratinib significantly improved annualized height velocity and height Z-scores compared with placebo in children with achondroplasia.